Press releases
These press releases are intended for journalists and analysts/investors.
-
TGA approves GSK’s combination of TAFINLAR®(dabrafenib) and MEKINIST® (trametinib)
GSK Australia announced today that the Therapeutics Goods Administration (TGA) has approved the combination of two oral targeted therapies
-
Supply of Varilrix® and Priorix-Tetra® resumes
GSK recently identified a global manufacturing issue impacting some of our varicella- containing vaccines during routine quality testing
-
Poppy Crop Security Update
GlaxoSmithKline (GSK) is aware that there may be an increased concern in poppy crop security following recent media reports
-
Supply of Varilrix® and Priorix-Tetra®
GSK recently identified a global manufacturing issue relating to some of our varicella-containing vaccines
-
GSK announces changes to its global sales and marketing practices
GSK announced today changes to the way products are marketed and sold to healthcare professionals to further align the company’s activities
-
Poppy Trials Making Positive Progress
Victoria is one step closer to commercial poppy growing, with scientific trials undertaken by GlaxoSmithKline (GSK) Australia
-
GSK recalls from trade two batches of Children’s Panadol® 1-5 years Suspension
GSK is working with the Therapeutic Goods Administration (TGA) to recall two batches of Children’s Panadol® 1-5 years Suspension
-
New medicine listed on the PBS for the treatment of metastatic melanoma in Australia
The listing of Tafinlar® (dabrafenib mesilate) on the Pharmaceutical Benefits Scheme (PBS) will lead to improved access to the medicine
-
URGENT SAFETY ALERT - Syringe Dosing Device for Children’s Panadol
GlaxoSmithKline (GSK) is initiating a recall of Children’s Panadol Baby Drops Syringe dosing device due to possible inaccurate placement
-
GSK award shines light on seismic change to epilepsy diagnosis
GSK has awarded Professor Ingrid Scheffer the 2013 GlaxoSmithKline Award for Research Excellence (ARE) for helping to transform
-
GSK Adult Immunisation Grants 2013
Four projects set to increase adult immunisation rates across Australia have received funding through the GSK 2013 Adult Immunisation Grants
-
Monash-GSK pharmaceutical partnership wins two prestigious National B-HERT Collaboration Awards
GSK Australia’s manufacturing R & D team and the Monash Institute of Pharmaceutical Sciences (MIPS) received two industry awards
-
TGA listing of Trobalt® (retigabine)
The Therapeutic Goods Administration (TGA) has registered Trobalt (retigabine)
-
SYDNEY BUSHFIRES: Access to Emergency Asthma Medication
GlaxoSmithKline (GSK), Asthma Foundation NSW and the Pharmacy Guild of Australia are working in partnership to provide asthma rescue
-
Asthma Patients Breathe New Life Into Old Puffers
More than 600,000 asthma sufferers across Victoria are set to breathe a little more easily knowing their old puffers will no longer
-
PROLIA® (denosumab) now approved for the treatment of osteoporosis in men
Amgen Australia and GlaxoSmithKline Australia (GSK) today announced the Therapeutic Goods Administration (TGA) has approved a new indication
-
Australian Medicine Icon is Back!
New Children’s Panadol® 1-5 Years Suspension Now on Shelf
-
GSK awards grant for Indigenous researcher at University of Melbourne
GlaxoSmithKline (GSK) Australia will award a capacity building grant to an Indigenous researcher from The University of Melbourne's School
-
Poppy Crop Security
GlaxoSmithKline (GSK) is aware that there may be an increased concern in poppy crop security from recent media reports in Tasmania
-
Tafinlar® (dabrafenib mesilate) registered for the treatment of metastatic melanoma in Australia
Tafinlar® (dabrafenib) has been approved by the Therapeutics Goods Administration (TGA) in Australia for the treatment of patients
